|Bid||69.4000 x 1200|
|Ask||69.5000 x 1300|
|Day's Range||68.85 - 71.12|
|52 Week Range||66.62 - 110.20|
|Beta (3Y Monthly)||1.46|
|PE Ratio (TTM)||18.11|
|Earnings Date||Jan 23, 2019 - Jan 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||107.90|
HENDERSON, NV / ACCESSWIRE / December 13, 2018 / Here is a list of several Biotech companies in the news that could make investors profits heading into the holiday season. We are highlighting: Endonovo ...
The pharmaceutical sector delivers two benefits that appeal to investors: reasonable P/E ratios and growth catalysts. Many pharma stocks have suffered as of late. Some have key drugs facing patent expirations.
The last few years have been a difficult ride for investors in large-cap biotech Celgene ( CELG ). Celgene is currently trading around $68 per share and has a market capitalization of $48 billion. Warning! GuruFocus has detected 2 Warning Signs with CELG.
Making money in stocks amid an uncertain market (see our 2019 outlook) will require careful choices. It will be difficult to top the revenue and earnings growth rates in 2019, for instance, and economic growth is expected to slow. That kind of environment requires investors to be discerning when it comes to their stock picks. Investors looking for the best stocks to buy for 2019 should start with these 19 companies. These firms, ranging from a money-center bank to a bargain-basement retailer, have solid prospects in 2019. We've also listed five stocks you should consider parting ways with. Check them out. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond
NEW YORK, Dec. 10, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / December 10, 2018 / U.S. stocks closed in the red on Friday as U.S. jobs report fell short of expectations and uncertainty over the U.S. -China trade talk spur markets lower. ...
Anheuser-Busch InBev (BUD), International Business Machines Corp. (IBM), Celgene Corp. (CELG) and American International Group Inc. (AIG) have declined to their three-year lows
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren’t very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]
Investing.com - Health care stocks took a dive midday after medical device company Cooper posted lower-than-expected results.
OncoMed's clinical trial failures prevented the Redwood City company from achieving the financial promise of deals with Celgene, Bayer and GlaxoSmithKline. Now a London company is reverse merging with it to get its NASDAQ listing and Peninsula facility.
J&J (JNJ) presents positive data from late-stage studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in the first-line setting at ASH.
This week, focus was on data presented at the annual conference of the American Society of Hematology from Dec 1-4. Apart from this, the regular pipeline updates were also in focus in the biotech sector.
Johnson & Johnson (JNJ) inks a global deal with Europe's argenx to jointly develop and globally commercialize the latter's prospective antibody, cusatuzumab.
Johnson & Johnson's blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed on Tuesday. The injection when used with standard of care drugs, Celgene Corp's Revlimid and dexamethasone, reduced the risk of the disease spreading or death by 44 percent at about 28 months in patients who are not eligible for stem cell transplant. At 30 months, the cancer did not spread in 71 percent of patients who were administered the Darzalex combination therapy, compared with 56 percent of patients on the standard of care treatment, the company said.